← Back to patent-cliff list
Setidegrasib
Tier C — Watch / tradeSetidegrasib
Astellas Pharma Inc.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KRAS G12D
Indications (approved)：Non-small cell lung cancer, Pancreatic cancer, 胰腺导管癌, Colorectal cancer, Solid tumour, Metastatic cancer
Regional status
US
Phase III
2026-02-17
EU
Phase III
2026-02-17
China
Phase III
2026-02-17
Japan
Phase III
2026-02-17
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Setidegrasib?
Approved indications include: Non-small cell lung cancer, Pancreatic cancer, 胰腺导管癌, Colorectal cancer, Solid tumour, Metastatic cancer.
When does the Setidegrasib patent expire?
No public expiry year is available for Setidegrasib yet; this page updates once verified.
How do I get a quote for Setidegrasib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29